OncoMatch/Clinical Trials/NCT05891769
99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT
Is NCT05891769 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies 18Fluorocholine for parathyroid adenoma.
Treatment: 18Fluorocholine — This study proposes the use of a well-established PET isotope, Fluorine-18 (18F), bound to Choline, for a prospective single-center, single-arm study for participants with suspected parathyroid adenoma and negative or equivocal standard of care 99mTc Sestamibi SPECT/CT
Check if I qualifyExtracted eligibility criteria
Lab requirements
Kidney function
Creatinine clearance < 60 mL/min or serum creatinine >1.5 x ULN [excluded]
Liver function
Total bilirubin ≤ 1.5 x upper limit of normal (ULN); ALT or AST ≤ 5 x ULN
Cardiac function
QTcF >470 msec on ECG or congenital long QT syndrome [excluded]
Total bilirubin ≤ 1.5 x upper limit of normal (ULN); ALT or AST ≤ 5 x ULN; Creatinine clearance < 60 mL/min or serum creatinine >1.5 x ULN [excluded]; QTcF >470 msec on electrocardiogram (ECG) or congenital long QT syndrome [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford Hospital and Clinics · Stanford, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify